Community Health Systems下调2026年收入和EBITDA指引并提示择期手术与未保险患者压力

Earnings Call Insights: Community Health Systems (CYH) Q2 2026
“Adjusted EBITDA was $330 million compared with $380 million in the prior year period on a 9.8% decline in net revenue, primarily reflecting a smaller prior period benefit from newly approved state-directed payment programs as well as divestitures completed over the past 12 months.” (President, CEO & Director Kevin Hammons)
“Same-store net revenue increased 2.4% over the prior year period. Same-store adjusted admissions increased 2.9%. However, approximately half of that volume growth was driven by uninsured visits with minimal related net revenue… resulting in a 0.5% decline in net revenue per adjusted admission for the quarter.” (President, CEO & Director Hammons)
“For the second quarter of 2026, financial results came in below our internal expectations… service and payer mix did not improve as expected, reflecting continued softness in elective procedures, along with higher uncompensated care, both of which drove lower margins.” (CFO & Executive VP Jason Johnson)
“In May, we completed a tender offer using proceeds from recent divestitures to repurchase approximately $368 million of the 4.75% Senior Secured Notes due 2031 and $231 million of the 10.875% Senior Secured Notes due 2032.” (CFO & Executive VP Johnson)
“During the quarter, we completed the previously announced divestiture of 4 hospitals in Arkansas for $110 million in cash and also completed the previously announced acquisitions of majority ownership percentages in Surgical Institute of Alabama in Birmingham and South Anchorage Surgery Center in Anchorage, Alaska.” (CFO & Executive VP Johnson)
“As noted in last night's press release, we are updating our financial guidance for 2026. Specifically, we now expect net revenue to be $11.4 billion to $11.6 billion and adjusted EBITDA in a range of $1.3 billion to $1.375 billion.” (CFO & Executive VP Johnson)
“We continue to believe that the non-ACA-related payer mix and service mix challenges that we experienced in the first half reflect a temporary disruption in demand… However… we believe it is prudent to be more cautious about the second half of the year and therefore, adjusted our full year outlook accordingly.” (President, CEO & Director Hammons)
“At the low end of our guidance, we assume that the '26 year is not able to be recognized by year-end. At the high end, we assume that we are able to recognize the Florida 2026 and the benefit is consistent with the amount that we just recognized in the second quarter.” (CFO & Executive VP Johnson)
“Adjusted EBITDA for the second quarter was $330 million with a margin of 11.7% versus 12.1% in the prior year period.” (CFO & Executive VP Johnson)
“Results include approximately $40 million to $45 million in combined EBITDA contribution from the recently approved Florida and Indiana state directed payment programs… Of this amount, approximately $20 million to $25 million related to prior periods… offset by an approximate $15 million reduction in the Arizona state-directed program because of the prior period true-up.” (CFO & Executive VP Johnson)
“Same-store surgeries declined 0.1% with a notable decline of 3.8% in inpatient surgeries.” (CFO & Executive VP Johnson)
“Cash flows from operations were $87 million for the second quarter or $143 million when adjusted to exclude cash taxes paid out of divestiture proceeds.” (CFO & Executive VP Johnson)
“The company's leverage at quarter end was 6.7x versus 6.6x at year-end 2025.” (CFO & Executive VP Johnson)
Michael Murray, RBC Capital Markets, Research Division: “What gives you confidence that the EPTC headwind doesn't worsen through the balance of the year…?” CFO Johnson: “So we estimate the quarter impact on the EBITDA front to be $20 million negative in the quarter… We do think the back half of the year looks like the second quarter… I feel comfortable with our increased range, which now sits between $50 million and $75 million of impact on an annual basis.”
Brian Tanquilut, Jefferies LLC, Research Division: “Could you help me bridge to that guide…?” CFO Johnson: “The miss in the first half of the year versus the expectations when we developed that guidance is between $60 million and $65 million… we took the second half down by $60 million to $70 million.”
Brian Tanquilut, Jefferies LLC, Research Division: “Curious how you're thinking about the drivers… on the cash flow side…?” President & CEO Hammons: “They're now auditing more claims before they pay them… So our AR is growing accordingly… we don't believe it's necessarily a collection issue. It's just a timing issue.”
Albert Rice, UBS Investment Bank, Research Division: “Can you break it down… and… any distinction… in the freestanding surgery centers…?” President & CEO Hammons: “Orthopedics being the largest decline… We are also seeing some softness in cardiac surgeries… we're seeing bigger declines in the inpatient side… our surgery centers are picking up, but it is kind of lower acuity surgeries.”
Albert Rice, UBS Investment Bank, Research Division: “Do you have any color on… admissions that are uninsured…?” President & CEO Hammons: “We were approximately 5% of our visits… prior year… and this year, we're about 110 basis points higher to just over 6% of visits.”
Jason Cassorla, Guggenheim Securities, LLC, Research Division: “Walk through… medical specialist fees…?” CFO Johnson: “The most significant component… anesthesia… when volumes are down… we have to pay the subsidy… the impact… was about $3 million of net revenue in the quarter… but it's still outpacing what we had expected.”
Jason Cassorla, Guggenheim Securities, LLC, Research Division: “Your thoughts around the proposed Medicare OPPS rule… 340B…?” President & CEO Hammons: “We think the net increase in outpatient rate for 2027 should be around 5%.”
Stephen Baxter, Wells Fargo Securities, LLC, Research Division: “More detail on the payer mix…?” President & CEO Hammons: “The increase in uninsured is primarily coming from the exchange business… There is also a decline in Medicaid… the softness in surgeries… is primarily commercially insured patients.”
Andrew Mok, Barclays Bank PLC, Research Division: “Can you elaborate… exit rate on surgeries…?” President & CEO Hammons: “June was our best month of the quarter… we were positive year-over-year in the month of June.”
John Ransom, Raymond James & Associates, Inc., Research Division: “Has the collectibility on self-pay deteriorated…?” President & CEO Hammons: “We only collect a few pennies on the dollar anyway… We're effectively not recognizing any revenue on that self-pay business.”
“What gives you confidence…” and “could you help me bridge…” reflected a slightly negative, probing analyst tone focused on the durability of ACA-related headwinds and the reduced full-year outlook. (Michael Murray, RBC; Brian Tanquilut, Jefferies)
Management’s prepared remarks were slightly positive on execution but cautious on demand and mix, including “financial results came in below our internal expectations” and “we believe it is prudent to be more cautious about the second half of the year.” (CFO & Executive VP Johnson; President, CEO & Director Hammons)
Compared with Q1, management language shifted from “Our financial guidance for 2026 remains unchanged” to “we are updating our financial guidance for 2026,” while analysts moved from early monitoring of EPTC/HIX impacts to more direct questions on the magnitude and persistence of the headwind. (CFO & Executive VP Johnson)
Q2 emphasized a reset in full-year expectations, with “we are updating our financial guidance for 2026,” versus Q1’s “Our financial guidance for 2026 remains unchanged.” (CFO & Executive VP Jason Johnson)
The operational narrative moved from Q1’s “Same-store surgeries declined 2.2%” and “ED visits were down 2.8%” to Q2’s “Same-store surgeries declined 0.1% with a notable decline of 3.8% in inpatient surgeries,” alongside heightened focus on uninsured volume growth. (CFO & Executive VP Johnson)
Strategic activity progressed from Q1’s “pending acquisition… Surgical Institute of Alabama” to Q2’s “completed… acquisitions… Surgical Institute of Alabama… and South Anchorage Surgery Center,” while divestiture actions continued with the Arkansas hospitals closing in Q2. (President, CEO & Director Kevin Hammons; CFO & Executive VP Johnson)
“An unexpected increase in uninsured volumes and continued softness in demand for elective surgical procedures among commercially insured patients” was framed as a key near-term operational headwind. (President, CEO & Director Hammons)
“They're now auditing more claims before they pay them… So our AR is growing accordingly,” highlighting payer payment timing risk and rising accounts receivable days. (President, CEO & Director Hammons)
“Medical specialist fees… outpaced our forecast,” with “Anesthesiology and radiology” cited as “the largest pain points in this regard.” (CFO & Executive VP Johnson)
Uncertainty around Florida’s state-directed program timing was embedded in guidance assumptions: “the plan hasn't been submitted to CMS yet.” (CFO & Executive VP Johnson)
CHS management described Q2 results as below internal expectations as payer and service mix remained pressured by higher uninsured volumes and softness in elective procedures, prompting an updated 2026 outlook for $11.4B-$11.6B in net revenue and $1.3B-$1.375B in adjusted EBITDA; executives also highlighted ongoing cost controls, recent debt repurchases, and completed divestitures and ASC acquisitions, while acknowledging risks from ACA-related exchange disenrollment behavior, slower payer payments that are extending AR timing, and elevated specialist-fee pressure in anesthesiology and radiology.